Activities per year
The coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Antibody testing plays a big role in understanding virus’s epidemiology and it reveals whether a patient’s immune system has developed antibodies against the virus. The main goal of this study was to evaluate antibody response to SARS-CoV-2 in dynamics.
Materials and Methods
In this study 155 patients (both hospitalized and outpatients) were analysed for the presence of virus-specific (IgG NCP, IgG S1 and IgA) antibodies using EUROIMMUN semi-quantitative ELISA. 168 patients’ plasma samples for virus-specific antibodies were quantified using quantitative ELISA (ANTIBODIES) for anti-SARS-CoV-2 IgG and IgM class antibodies.
In 123 (79.35%) COVID-19 patients’ plasma samples anti-SARS-CoV-2 IgG NCP, in 122 (78.71%) - anti-SARS-CoV-2 IgG S1 and in 117 (75.48%) - anti-SARS-CoV-2 IgA class antibodies were detected. 23 of 155 patients had been tested for antibodies repeatedly. The highest number of IgA positive plasma samples were among those collected after 5-12 days, the lowest number – after 63 – 85 days from the disease onset. There are slight differences in the IgG antibody response to the two SARS-CoV-2 antigens (against S1 and NCP) tested. 168 patients had been tested for antibodies in dynamics. IgM class antibody titters decreased after about 2 months of observation. Also, a decreasing tendency of IgG class antibody titters in patients’ plasma samples was observed after about 2 months, but in some patient plasma samples IgG class antibodies remain detectable until ~6 months. In one patient sample collected after two months, IgM antibodies had reappeared.
IgM titter decreased after about 2 months when a decreasing tendency in some of the cases was also observed for IgG. In some cases, IgG antibodies remain detectable until ~6 months. Repeated IgM production can indicate a possible COVID-19 reinfection/reactivation in some patients.
|Number of pages||1|
|Publication status||Published - 17 Jun 2021|
|Event||WSV Conference 2021 - Tackling Global Viral Epidemics - , South Africa|
Duration: 16 Jun 2021 → 19 Jun 2021
|Conference||WSV Conference 2021 - Tackling Global Viral Epidemics|
|Period||16/06/21 → 19/06/21|
Field of Science
- 3.2 Clinical medicine
- 3.3 Health sciences
- 3.4. Other publications in conference proceedings (including local)
FingerprintDive into the research topics of 'Characterization Of Antibody Responses To SARS-CoV-2 Infection In Covid-19 Patients In Latvia'. Together they form a unique fingerprint.
- 1 Oral presentation
Samanta Strojeva (Speaker)16 Jun 2021 → 18 Jun 2021
Activity: Talk or presentation types › Oral presentation